Edition:
United Kingdom

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

125.03USD
20 Aug 2018
Change (% chg)

$-0.58 (-0.46%)
Prev Close
$125.61
Open
$126.33
Day's High
$126.33
Day's Low
$124.42
Volume
126,543
Avg. Vol
147,682
52-wk High
$152.55
52-wk Low
$100.64

Chart for

About

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $5,381.27
Shares Outstanding(Mil.): 43.44
Dividend: --
Yield (%): --

Financials

  UTHR.OQ Industry Sector
P/E (TTM): 14.44 85.68 32.76
EPS (TTM): 8.58 -- --
ROI: 20.98 1.78 14.61
ROE: 21.85 3.28 16.33

BRIEF-United Therapeutics Reports Q1 Adj. Earnings Per Share Of $3.76

* Q1 EARNINGS PER SHARE VIEW $3.52 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-United Therapeutics To Acquire SteadyMed Ltd

* UNITED THERAPEUTICS-TRANSACTION, INCLUDING $75 MILLION IN CONTINGENT CONSIDERATION, IS VALUED AT $216 MILLION

30 Apr 2018

BRIEF-United Therapeutics Says CEO Martine Rothblatt's FY 2017 Total Compensation Was $37.1 Mln

* UNITED THERAPEUTICS SAYS CEO MARTINE ROTHBLATT'S FY 2017 TOTAL COMPENSATION WAS $37.1 MILLION WHICH INCLUDED $33.1 MILLION IN OPTION/STAP AWARDS - SEC FILING

27 Apr 2018

BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin

* UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING Source text: (https://bit.ly/2E6Hb6r) Further company coverage:

30 Mar 2018

BRIEF-United Therapeutics Corp Reports Qtrly EPS Of $0.43

* Q4 EARNINGS PER SHARE VIEW $3.89, REVENUE VIEW $421.7 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

21 Feb 2018

Earnings vs. Estimates